), the leading innovator and provider of naturally sourced supplements based on
Real Food Technology®
solutions, recently presented product research at the 9
Annual International Society of Sports Nutrition Conference and Expo, which was held in Clearwater, Fla., on June 22-23, 2012.
The open-label human clinical trial showed that intake of Mannatech products resulted in statistically significant improvements in numerous self-reported measures of physical and mental health, quality of life, memory, and elbow and knee pain reduction.*
The 15 retired football players who participated in the study took Mannatech’s
complex powder, Omega-3 with Vitamin D
, Ambrotose AO
caplets and PLUS™ caplets.
The study was authored by Dr. Robert Sinnott, Dr. Rolando L. Maddela, Dr. Sejong Bae and Dr. Talitha Best. Dr. Sinnott is the CEO and Chief Science Officer at Mannatech, and Dr. Maddela is the Clinical Research Administration Manager at Mannatech. Dr. Bae is a Professor in the Department of Biostatistics at the University of North Texas Health Science Center’s School of Public Health in Fort Worth, Texas; Dr. Best is a Research Fellow in the Nutritional Physiology Research Center, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia.
The International Society of Sports Nutrition’s annual conference and expo brings together scientists, physicians and athletes interested in sharing the latest science evaluating nutritional and behavioral approaches to optimizing human health and performance. More information about the meeting can be found here:
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
This study was funded by Mannatech.
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico and Namibia. For more information, visit
Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “believe,” “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.